Vir Biotechnology Inc (VIR)
9.93
-0.09
(-0.90%)
USD |
NASDAQ |
May 16, 16:00
9.945
+0.02
(+0.15%)
After-Hours: 20:00
Vir Biotechnology Enterprise Value: 201.30M for May 16, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 16, 2024 | 201.30M |
| May 15, 2024 | 213.55M |
| May 14, 2024 | 221.71M |
| May 13, 2024 | 179.53M |
| May 10, 2024 | 134.63M |
| May 09, 2024 | 150.96M |
| May 08, 2024 | 148.24M |
| May 07, 2024 | 201.30M |
| May 06, 2024 | 240.76M |
| May 03, 2024 | 263.89M |
| May 02, 2024 | 99.26M |
| May 01, 2024 | 39.39M |
| April 30, 2024 | 1.294M |
| April 29, 2024 | -10.95M |
| April 26, 2024 | -30.00M |
| April 25, 2024 | -113.27M |
| April 24, 2024 | -57.58M |
| April 23, 2024 | -45.35M |
| April 22, 2024 | -49.43M |
| April 19, 2024 | -69.80M |
| April 18, 2024 | -68.44M |
| April 17, 2024 | -29.05M |
| April 16, 2024 | -14.11M |
| April 15, 2024 | 14.42M |
| April 12, 2024 | 68.76M |
| Date | Value |
|---|---|
| April 11, 2024 | 105.44M |
| April 10, 2024 | 85.06M |
| April 09, 2024 | 144.83M |
| April 08, 2024 | 139.40M |
| April 05, 2024 | 119.02M |
| April 04, 2024 | 136.68M |
| April 03, 2024 | 166.57M |
| April 02, 2024 | 157.06M |
| April 01, 2024 | 235.85M |
| March 31, 2024 | 226.33M |
| March 28, 2024 | -154.53M |
| March 27, 2024 | -158.58M |
| March 26, 2024 | -176.14M |
| March 25, 2024 | -172.09M |
| March 22, 2024 | -165.33M |
| March 21, 2024 | -159.93M |
| March 20, 2024 | -149.13M |
| March 19, 2024 | -172.09M |
| March 18, 2024 | -80.26M |
| March 15, 2024 | -69.46M |
| March 14, 2024 | -101.87M |
| March 13, 2024 | -43.81M |
| March 12, 2024 | -73.51M |
| March 11, 2024 | 16.96M |
| March 08, 2024 | 11.56M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-652.67M
Minimum
Oct 27 2023
9.848B
Maximum
Jan 27 2021
2.400B
Average
1.773B
Median
Apr 25 2022
Enterprise Value Benchmarks
| Vertex Pharmaceuticals Inc | 103.54B |
| Vistagen Therapeutics Inc | -3.594M |
| Immuneering Corp | -25.61M |
| SeaStar Medical Holding Corp | 39.22M |
| NovaBay Pharmaceuticals Inc | 5.209M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -65.28M |
| Revenue (Quarterly) | 51.20M |
| Total Expenses (Quarterly) | 131.28M |
| EPS Diluted (Quarterly) | -0.48 |
| Gross Profit Margin (Quarterly) | 99.88% |
| Profit Margin (Quarterly) | -127.5% |
| Earnings Yield | -40.38% |
| Normalized Earnings Yield | -39.47 |